Related Experiment Video
Updated: Sep 10, 2025
Quantification of Coenzyme A in Cells and Tissues
Published on: September 27, 2019
Analysis of hydroxocobalamin dosage in patients with CblC deficiency
Si Ding1, Yuxin Deng2, Yi Ding2
1Department of Pediatric Infection, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 KongJiang Road, Shanghai, 200092, China.
Insights
Hydroxocobalamin (OHCbl) dosage for cblC deficiency is influenced by disease onset and specific gene variants. This study provides dosage references for stable periods, aiding treatment decisions in this common organic acidemia.
Area of Science:
- Biochemistry
- Genetics
- Clinical Medicine
Background:
- cblC deficiency is the most prevalent organic acidemia in China.
- Hydroxocobalamin (OHCbl) is a primary therapeutic agent for cblC deficiency.
- Established protocols for OHCbl dosage during stable periods are lacking.
Purpose of the Study:
- To analyze OHCbl dosage in patients with cblC deficiency during stable periods.
- To identify factors influencing OHCbl dosage.
- To provide a reference for selecting OHCbl dosages.
Main Methods:
- Enrolled 730 patients with cblC deficiency in stable condition.
- Employed univariate and multiple linear regression analyses.
- Investigated correlations between OHCbl dosage and newborn screening, disease onset, and MMACHC gene mutations.
Main Results:
- Disease onset and the c.482G>A variant were identified as independent factors affecting OHCbl dosage.
- Median OHCbl dosage was 1.18 mg/kg/week.
- Patients with the c.482G>A variant received lower dosages (0.31 mg/kg/week) compared to those without (1.37 mg/kg/week).
Conclusions:
- Identified key factors influencing OHCbl dosage in cblC deficiency.
- Offers a reference for optimizing OHCbl dosage strategies.
- Highlights the impact of genetic variants and disease presentation on treatment.
Objective:
cblC deficiency is the most common organic acidemia in China. Hydroxocobalamin (OHCbl) is the main important therapeutic approach, while no approved protocols on its dosage during stable periods exist. This study aims to analyze OHCbl dosage and explore its influencing factors, providing reference for the option of OHCbl dosage.
Methods:
A total of 730 patients with cblC deficiency during stable periods were enrolled. Univariate analysis and multiple linear regression analysis were used to investigate the correlation between OHCbl dosage and tandem mass spectrometry (MS/MS)-based newborn screening (NBS), disease onset as well as MMACHC gene mutation.
Results:
Univariate analysis revealed no significant difference in OHCbl dosage between whether patients were diagnosed by MS/MS-based NBS or not, while significant differences were found based on disease onset and the presence of c.482G > A variant. Multiple linear regression analysis further identified disease onset and the c.482G > A variant as independent factors influencing OHCbl dosage. The median OHCbl dosage during stable periods was 1.18 mg/kg/week, with 0.31 mg/kg/week in patients with the c.482G > A variant and 1.37 mg/kg/week in those without. However, in patients carrying the c.482G > A variant, there was no significant difference in the OHCbl dosage between those with and without disease onset, while in patients without the c.482G > A variant, those with disease onset had a higher OHCbl dosage compared to those without.
Conclusion:
The study demonstrated the independent influencing factors of OHCbl dosage in patients with cblC deficiency and put forward corresponding reference for the option of OHCbl dosage.
Related Concept Videos
01:30Vitamins
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...